ArticleAntimicrobial agents and chemotherapy2018
Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- A Fivefold Maximum Drug-Likeness Strategy for Prioritizing Antibacterial Candidates AgainstPharmaceuticals (Basel, Switzerland) · 2026Article
- The BaeSR two-component system activatesmBio · 2026Article
- Identification of Antibacterial Hits Associated with Penicillin-Binding Protein 2 inDrug design, development and therapy · 2026Article
- Revealing the potential value of urine microbiota in ureteral stent encrustation after renal transplantation via Illumina sequencing of 16S rRNA genes.BMC microbiology · 2025Article
- In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol.The Journal of antibiotics · 2024Article
- Insights into Kinases of ESKAPE Pathogens for Therapeutic Interventions.Cardiovascular & hematological agents in medicinal chemistry · 2024Review
- Filamentous morphology of bacterial pathogens: regulatory factors and control strategies.Applied microbiology and biotechnology · 2022Review
- Article
- Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Review
- Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales.Infection and drug resistance · 2021Review
- Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-β-Lactamase-Producing Escherichia coli Isolates.Antimicrobial agents and chemotherapy · 2020Article
- Therapeutic Effect and Mechanisms of the Novel Monosulfactam 0073.Antimicrobial agents and chemotherapy · 2020Article
- Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline.Antimicrobial agents and chemotherapy · 2020Review
- An Intertwined Network of Regulation Controls Membrane Permeability Including Drug Influx and Efflux in Enterobacteriaceae.Microorganisms · 2020Review
- New strategies and structural considerations in development of therapeutics for carbapenem-resistant Enterobacteriaceae.Translational research : the journal of laboratory and clinical medicine · 2020Review
- Antibiotics in the clinical pipeline in October 2019.The Journal of antibiotics · 2020Review
- Complex Response of the CpxAR Two-Component System to β-Lactams on Antibiotic Resistance and Envelope Homeostasis inAntimicrobial agents and chemotherapy · 2020Article
- Critical analysis of antibacterial agents in clinical development.Nature reviews. Microbiology · 2020Review
- Stepwise evolution and convergent recombination underlie the global dissemination of carbapenemase-producing Escherichia coli.Genome medicine · 2020Article
- Identification of Mutations in themSphere · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The monobactam scaffold is attractive for the development of new agents to treat infections caused by drug-resistant Gram-negative bacteria because it is stable to metallo-β-lactamases (MBLs). However, the clinically used monobactam aztreonam lacks stability to serine β-lactamases (SBLs) that are often coexpressed with MBLs. LYS228 is stable to MBLs and most SBLs. LYS228 bound purified
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.